Clinical TrialJun 15, 2026, 06:51 AM
Pharvaris Deucrictibant Phase 3 RAPIDe-3 Shows Rapid HAE Attack Relief
AI Summary
Pharvaris presented positive data from its deucrictibant clinical program at the EAACI Annual Congress 2026. The Phase 3 RAPIDe-3 study for on-demand treatment of HAE attacks demonstrated rapid and sustained efficacy, with a median time to symptom relief of 1.28 hours and a median time to End of Progression (EoP) of 17.47 minutes. Additionally, long-term data from the CHAPTER-1 open-label extension study showed sustained efficacy, reducing HAE attack rates by approximately 92%, and a favorable cardiovascular safety profile across all studies.
Key Highlights
- Deucrictibant achieved median time to symptom relief of 1.28 hours vs. >12 hours for placebo in RAPIDe-3.
- Median time to complete symptom resolution was 11.95 hours vs. >48 hours for placebo in RAPIDe-3.
- 83.0% of deucrictibant-treated attacks in RAPIDe-3 were managed with a single capsule.
- Median time to End of Progression (EoP) was 17.47 minutes vs. 228.67 minutes for placebo.
- Long-term treatment with deucrictibant reduced HAE attack rates by ~92% in CHAPTER-1 OLE.
- Approximately half of CHAPTER-1 OLE participants were attack-free during the entire extension period.
- 100% of CHAPTER-1 OLE participants reported well-controlled disease during long-term treatment.
- Integrated analysis showed a favorable cardiovascular safety profile across ~570 deucrictibant-treated participants.
Price Impact
More from PHVS